

Early Clinical Experience Scholarly Project:

Students learn from patients and
clinics learn from students

Migdalisel Colón-Berlinger, PhD
Mindy Chilman McComb, DO

Randi Stanulis, Stacey Pylman, Kari Chandler, and Robin DeMuth

Michigan State University College of Human Medicine

Preparing today's learners for tomorrow's practice


1

Overview

- Context:
 - The Shared Discovery Curriculum
 - The Early Clinical Experience (ECE)
- The Problem
- Project Implementation
- Next Steps
- Interactive Poster Review
- Potential Applications at Other Institutions
- Q&A

2

Introduction to the Shared Discovery Curriculum



3

Early Clinical Experience (1 of 2)



SHARED DISCOVERY
CURRICULUM

- 1st 24 weeks of medical school:
 - 8 week preparatory experience
 - To be safe and helpful
 - 16 week longitudinal ambulatory experience
- Work with the health care team
 - Medical assistants, nurses, office staff, physicians, etc.
- Perform clinical tasks
 - Vitals, med rec, point-of-care testing
- See and learn from patients
 - Medical diagnoses, medications, social context, etc.
- Discuss experiences in Post Clinic Groups twice weekly

4

Early Clinical Experience (2 of 2)



- Other activities include:
 - Weekend learning module
 - Large group activity
 - Post clinic groups
 - Gross anatomy lab
 - Virtual imaging and physiology lab
 - Simulation
 - Clinic (Early Clinical Experience)
 - Guided independent learning
 - Weekly formative assessments
- Preparation is key for active learning
- In-class experiences utilize flipped classroom methodologies

5

A Missing Piece?




6

The ECE Scholarly Project: The Problem

- A way for students to delve deeper into questions raised in their clinical settings, but...
 - Inherent challenges with a short timeline
 - Complete a meaningful project in 2-3 months
 - Preceptors with varying levels of interest
 - Students placed at >100 ambulatory clinical sites
 - First-year medical students
 - Some without project or presentation experience
- ...and they're still in a rigorous medical school curriculum!

7

The ECE Scholarly Project: Implementation



8


Poster Presentations

Methodologies

- Quality Improvement (QI)
- Patient Education
- Literature Review
- Case Presentation

Topics

- Diabetes
- Immunizations
- Mental health/Screening
- Hypertension
- Handwashing
- No shows, patient portal, scheduling, wait time, team dynamics, patient satisfaction
- Language/interpreters
- Opioids



9

The ECE Scholarly Project: Unanticipated Challenges

- Everyone thought they needed to do a QI project
 - Maybe because of discussing QI vs. Research?
 - A lot of faculty effort to ensure QI projects were appropriate
- Many students wanted to survey patients
 - Required a clearcut QI format
 - Will not be allowed in 2nd iteration -- ultimately for protection of patients, also to reduce stress on faculty
- Students with previous research experience felt limited in scope
 - Option to take their project further in MCE or LCE

10

Next Steps

	Prior to week 8	Information available online
Students start in clinic	Week 8	Orientation
	Week 9	
Checklist	Week 10	
	Week 11	Workshop: define your focus question
One page proposal	Week 12	
	Week 13	
	Week 15	Proposal feedback
Revised proposals	Week 16	
	Holiday break	
	Week 17	Quantitative and qualitative data analysis modules (available prior to week 8)
	Week 18	
	Week 19	Office hours: Data analysis and poster preparation
	Week 20	
	Week 21	
Poster submissions	Week 22	
	Week 23	
Poster presentations	Week 24	

11

Interactive Poster Review

ECE Scholarly Project Poster Review Form

Name of Reviewer: _____
 Poster Number: _____ Title/student name: _____

Key:
 1- Poor
 2- Below Average
 3- Average, Meets Expectations
 4- Above Average
 5- Truly Exceptional

	(-)	(+)
Does the poster include: 1) Title, 2) Focus Question, 3) Methods, 4) Conclusions, 5) Acknowledgements, and 6) References? (<i>One point for each</i>)	1	2 3 4 5 6
Is the focused question related to an observation made in the clinical setting as part of the ECE clinical experience?	No	So-so Yes 1 3 5
Are the data collection methods (methodology) designed appropriately to address the focused question?	1	2 3 4 5
Are the data/results presented clearly?	1	2 3 4 5
Is there a clear explanation of the results?	1	2 3 4 5
Do conclusions seem well supported by data?	1	2 3 4 5
Is the poster attractive and easy to read and understand?	1	2 3 4 5
Was the oral presentation clear, succinct, and appropriate?	1	2 3 4 5
Was the presenter able to answer questions in an informed manner?	1	2 3 4 5

12

College of Human Medicine
MICHIGAN STATE UNIVERSITY

Paraneoplastic Cough in a Patient with Renal Cell Carcinoma

Introduction

Renal cell carcinoma (RCC) is a cancer which can present with a classic triad of flank pain, hematuria, and a palpable abdominal mass. However, this is seen in only 45 percent of patients. RCC is more frequently accompanied by various paraneoplastic syndromes and symptoms.

Endocrine symptoms:

- Hypercalcemia
- Hypertension
- Chilling syndrome

Immunologic symptoms:

- Fever
- Anemia
- Cachexia

Diagnosis is often accidental and is made when patients undergo imaging for other unrelated symptoms (Figure 1).

As a result, reporting of RCC presenting with paraneoplastic cough has been limited and inconsistent. One common theme among all cases we reviewed was that the cough developed following removal of the tumor, occurring in our 65-year-old female patient.

Case Timeline

Figure 1: A timeline diagram showing the patient's history and case timeline. The timeline starts with the patient's history of chronic kidney disease (CKD) and hypertension (HTN) for 20 years. At 2 weeks, the patient was diagnosed with RCC. At 4 weeks, the patient was diagnosed with a paraneoplastic cough. At 6 weeks, the patient was diagnosed with a paraneoplastic cough. At 8 weeks, the patient was diagnosed with a paraneoplastic cough. At 10 weeks, the patient was diagnosed with a paraneoplastic cough. At 12 weeks, the patient was diagnosed with a paraneoplastic cough. At 14 weeks, the patient was diagnosed with a paraneoplastic cough. At 16 weeks, the patient was diagnosed with a paraneoplastic cough. At 18 weeks, the patient was diagnosed with a paraneoplastic cough. At 20 weeks, the patient was diagnosed with a paraneoplastic cough. At 22 weeks, the patient was diagnosed with a paraneoplastic cough. At 24 weeks, the patient was diagnosed with a paraneoplastic cough. At 26 weeks, the patient was diagnosed with a paraneoplastic cough. At 28 weeks, the patient was diagnosed with a paraneoplastic cough. At 30 weeks, the patient was diagnosed with a paraneoplastic cough. At 32 weeks, the patient was diagnosed with a paraneoplastic cough. At 34 weeks, the patient was diagnosed with a paraneoplastic cough. At 36 weeks, the patient was diagnosed with a paraneoplastic cough. At 38 weeks, the patient was diagnosed with a paraneoplastic cough. At 40 weeks, the patient was diagnosed with a paraneoplastic cough. At 42 weeks, the patient was diagnosed with a paraneoplastic cough. At 44 weeks, the patient was diagnosed with a paraneoplastic cough. At 46 weeks, the patient was diagnosed with a paraneoplastic cough. At 48 weeks, the patient was diagnosed with a paraneoplastic cough. At 50 weeks, the patient was diagnosed with a paraneoplastic cough. At 52 weeks, the patient was diagnosed with a paraneoplastic cough. At 54 weeks, the patient was diagnosed with a paraneoplastic cough. At 56 weeks, the patient was diagnosed with a paraneoplastic cough. At 58 weeks, the patient was diagnosed with a paraneoplastic cough. At 60 weeks, the patient was diagnosed with a paraneoplastic cough. At 62 weeks, the patient was diagnosed with a paraneoplastic cough. At 64 weeks, the patient was diagnosed with a paraneoplastic cough. At 66 weeks, the patient was diagnosed with a paraneoplastic cough. At 68 weeks, the patient was diagnosed with a paraneoplastic cough. At 70 weeks, the patient was diagnosed with a paraneoplastic cough. At 72 weeks, the patient was diagnosed with a paraneoplastic cough. At 74 weeks, the patient was diagnosed with a paraneoplastic cough. At 76 weeks, the patient was diagnosed with a paraneoplastic cough. At 78 weeks, the patient was diagnosed with a paraneoplastic cough. At 80 weeks, the patient was diagnosed with a paraneoplastic cough. At 82 weeks, the patient was diagnosed with a paraneoplastic cough. At 84 weeks, the patient was diagnosed with a paraneoplastic cough. At 86 weeks, the patient was diagnosed with a paraneoplastic cough. At 88 weeks, the patient was diagnosed with a paraneoplastic cough. At 90 weeks, the patient was diagnosed with a paraneoplastic cough. At 92 weeks, the patient was diagnosed with a paraneoplastic cough. At 94 weeks, the patient was diagnosed with a paraneoplastic cough. At 96 weeks, the patient was diagnosed with a paraneoplastic cough. At 98 weeks, the patient was diagnosed with a paraneoplastic cough. At 100 weeks, the patient was diagnosed with a paraneoplastic cough.

Discussion

Paraneoplastic syndromes are common in RCC, including symptoms in the lungs or pulmonary system. Several hypotheses regarding the cause of the cough in RCC have been proposed, such as mass effect by the tumor compressing the diaphragm or production of cytokines by the tumor itself. It is well known that ACE inhibitor treatment can result in chronic cough and a distinctive cough, but our patient was on lisinopril for several years without the emergence of a cough, making this less likely to be the cause.

However, the patient was found to have Sherrill's syndrome, a syndrome of lung dysfunction that occurs in patients with RCC and is essentially idiopathic. It is important to note that Sherrill's syndrome is caused by a mutation in the *ACE2* gene, not the *ACE* gene. This gene is located on chromosome 10p15.1, which is the same location as the *ACE* gene. This mutation is thought to be the cause of the syndrome.

References

1. American Cancer Society. Cancer Facts and Figures 2018. Atlanta: American Cancer Society; 2018.
2. National Cancer Institute. Renal Cell Carcinoma. Bethesda, MD: National Cancer Institute; 2018.
3. American Lung Association. Cough. Washington, DC: American Lung Association; 2018.
4. National Cancer Institute. Paraneoplastic Syndromes. Bethesda, MD: National Cancer Institute; 2018.
5. American Cancer Society. Renal Cell Carcinoma. Atlanta: American Cancer Society; 2018.
6. National Cancer Institute. Renal Cell Carcinoma. Bethesda, MD: National Cancer Institute; 2018.
7. American Lung Association. Cough. Washington, DC: American Lung Association; 2018.
8. National Cancer Institute. Paraneoplastic Syndromes. Bethesda, MD: National Cancer Institute; 2018.
9. American Cancer Society. Renal Cell Carcinoma. Atlanta: American Cancer Society; 2018.
10. National Cancer Institute. Renal Cell Carcinoma. Bethesda, MD: National Cancer Institute; 2018.
11. American Lung Association. Cough. Washington, DC: American Lung Association; 2018.
12. National Cancer Institute. Paraneoplastic Syndromes. Bethesda, MD: National Cancer Institute; 2018.
13. American Cancer Society. Renal Cell Carcinoma. Atlanta: American Cancer Society; 2018.
14. National Cancer Institute. Renal Cell Carcinoma. Bethesda, MD: National Cancer Institute; 2018.
15. American Lung Association. Cough. Washington, DC: American Lung Association; 2018.
16. National Cancer Institute. Paraneoplastic Syndromes. Bethesda, MD: National Cancer Institute; 2018.
17. American Cancer Society. Renal Cell Carcinoma. Atlanta: American Cancer Society; 2018.
18. National Cancer Institute. Renal Cell Carcinoma. Bethesda, MD: National Cancer Institute; 2018.
19. American Lung Association. Cough. Washington, DC: American Lung Association; 2018.
20. National Cancer Institute. Paraneoplastic Syndromes. Bethesda, MD: National Cancer Institute; 2018.

Acknowledgements

We thank Dr. [Name] for his assistance in the diagnosis and treatment of this patient.

17

Discussion

- Feasibility and applications at other institutions?

18

Questions?

Thank you!

19